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BACKGROUND: We examined plasma microRNA (miRNA) concentrations from patients with gastric cancers (GCs) to assess their
clinical application for diagnosing and monitoring diseases.
METHODS: We initially investigated the appropriateness of plasma miRNA assay, and then compared plasma miRNA results with the
expressions in cancer tissues from eight GC patients, and also compared plasma miRNAs between pre- and post-operative paired
samples from 10 GC patients. Then, plasma miRNAs (miR-17-5p, miR-21, miR-106a, miR-106b and let-7a) were analysed in 69 GC
patients and 30 healthy volunteers in total.
RESULTS: The initial analysis showed that miRNAs were stable and detectable in all plasma samples, and the plasma miRNA levels
reflected the tumour miRNAs in most cases. The levels of these miRNAs were significantly reduced in post-operative samples. In
large-scale analysis, the plasma concentrations of miRNAs (miR-17-5p, miR-21, miR-106a, miR-106b) were significantly higher in GC
patients than controls (P¼0.05, 0.006, 0.008 and o0.001 respectively), whereas let-7a was lower in GC patients (P¼0.002). The
values of the area under the receiver-operating characteristic curve were 0.721 for the miR-106b assay and 0.879 for the miR-106a/
let-7a ratio assay.
CONCLUSION: Detection of circulating miRNAs might provide new complementary tumour markers for GC.
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Gastric cancer (GC) is the second leading cause of cancer-related
death in the world (Parkin et al, 2005). Recent advances in
diagnostic techniques and peri-operative management have
increased the early detection of GC and decreased the mortality
rate. However, patients with advanced disease still frequently
develop recurrent disease after extended radical resections, and
consequently show extremely poor survival rates (Martin et al,
2002). Thus, the primary tumours must be detected at an early
stage, and recurrent disease must be diagnosed when it is still
minimal or clinically occult, to improve the cure rates for patients
with GCs.
For GC, serum tumour markers, such as carcinoembryonic
antigen and carbohydrate antigen 19-9, have been used as
convenient diagnostic assays (Nakane et al, 1994; Marrelli et al,
2001). These conventional serum markers, however, lack sufficient
sensitivity and specificity to facilitate early detection of cancer. In
addition, there are no other less invasive diagnostic tests for GC
such as faecal occult blood tests for colon cancer.
Recently, several studies have shown that microRNAs
(miRNAs), which are involved in tumourigenesis and the
development of various cancers, are stably detectable in plasma/
serum (Calin and Croce, 2006; Chen et al, 2008; Filipowicz et al,
2008). Mitchell et al (2008) clearly showed that circulating miRNAs
originate from cancer tissues, and are protected from endogenous
RNase activity by unknown mechanisms. They also showed the
potential of using plasma/serum miRNAs as a non-invasive blood-
based biomarker for the detection of prostate cancer. These
findings have opened up a new and interesting field in the
screening and monitoring of cancer patients.
In this study, we investigated the amounts of circulating
miRNAs in plasma samples from both pre-operative GC patients
and controls, and compared the relationships between the results
and clinical findings to assess the diagnostic value of these
biomarkers in patients with GCs.
MATERIALS AND METHODS
Patients and samples
Pre-operative plasma samples were collected from 34 patients with
GCs, who underwent gastrectomy at Kyoto Prefectural University
of Medicine, as well as from 15 healthy volunteers for test-scale
analysis. To evaluate the appropriateness of this plasma miRNA
assay, we initially investigated the level of three miRNAs, such as
miR-21, miR-106b and let-7a, in plasma samples by real-time
RT-PCR assay using the synthetic miRNAs, mirVana miRNA
Reference Panel (Ambion, Austin, TX, USA). Thereafter, we
performed two experiments to examine whether the plasma
miRNAs could reflect tumour dynamics. First, formalin-fixed
paraffin-embedded tumour samples were collected from eight
patients with higher levels of plasma miR-106b and lower levels of
plasma let-7a than healthy volunteers, and compared the miRNA
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Second, paired plasma samples before and 1 month after
gastrectomy were collected from 10 of the test-scale patients,
and findings in pre- and post-operative plasma samples were
compared. The initial experiments showed that plasma miRNA
assays were feasible and could reflect tumour dynamics, and then
we performed a large-scale validation in the next step.
Pre-operative plasma samples were collected from another 35
patients with GCs for further large-scale analyses, as well as from
another 15 healthy volunteers. Thus, between October 2008 and
July 2009, 69 patients with GC and 30 healthy volunteers were
enrolled in this study. We added another two miRNAs, miR-17-5p
and miR-106a, as candidates for biomarkers for large-scale
analyses. A peripheral blood sample was collected from patients
and volunteers after obtaining informed consent and agreement.
Immediately after collection, the blood samples were subjected to
isolation of cell-free nucleic acids using a three-spin protocol
(1500r.p.m. for 30min, 3000r.p.m. for 5min, 4500r.p.m. for
5min) to prevent contamination by cellular nucleic acids. Plasma
samples were then stored at  801C until further processing. None
of the patients had received chemotherapy or radiotherapy before
blood sampling. The resected GC specimens were fixed in buffered
formalin and embedded in paraffin for pathological examination
by standard methods. Macroscopic and microscopic classifications
of tumours were based on the IGCC/TMN staging system (Sobin
and Wittekind, 2002).
RNA extraction
Total RNA was extracted from 400ml of plasma using mirVana
PARIS Kit (Ambion), and finally eluted into 100ml of pre-heated
(951C) Elution Solution according to the manufacturer’s protocol.
As for formalin-fixed paraffin-embedded tissues, total RNA was
extracted from four slices 15mm thick (total 60mm in thickness)
using RecoverAll Total Nucleic Acid Isolation Kit (Ambion), and
eluted finally into 60ml of Elution Solution according to the
manufacturer’s protocol.
Protocols for the detection of miRNAs
The amounts of miRNAs were quantified in duplicate by qRT-PCR
using the human TaqMan MicroRNA Assay Kits (Applied
Biosystems, Foster City, CA, USA). The reverse transcription
reaction was carried out with TaqMan MicroRNA Reverse
Transcription Kit (Applied Biosystems) in 15ml containing 5ml
of RNA extract, 0.15ml of 100mM dNTPs, 1ml of Multiscribe
Reverse Transcriptase (50Uml
 1), 1.5mlo f1 0 reverse transcrip-
tion buffer, 0.19ml of RNase inhibitor (20Uml
 1), 1ml of gene-
specific primer and 4.16ml of nuclease-free water. For synthesis of
cDNA, the reaction mixtures were incubated at 161C for 30min, at
421C for 30min, at 851C for 5min and then held at 41C. Then,
1.33ml of cDNA solution was amplified using 10ml of TaqMan
2 Universal PCR Master Mix with no AmpErase UNG (Applied
Biosystems), 1ml of gene-specific primers/probe and 7.67mlo f
nuclease-free water in a final volume of 20ml. Quantitative PCR
was run on a 7300 Real-Time PCR system (Applied Biosystems)
and the reaction mixtures were incubated at 951C for 10min,
followed by 40 cycles of 951C for 15s and 601C for 1min. The cycle
threshold (Ct) values were calculated with the SDS 1.4 software
(Applied Biosystems).
The amounts of plasma miRNAs were calculated on a standard
curve constructed with the use of synthetic miRNAs, mirVana
miRNA Reference Panel (Ambion). The standard reference
miRNAs were amplified for each reaction. However, the expression
of miRNAs from tissue samples was normalised using the 2 DDCt
method relative to RNU6B. The DCt was calculated by subtracting
the Ct values of RNU6B from the Ct values of the miRNAs of
interest. The DDCt was then calculated by subtracting DCt of the
surrounding normal gastric epithelium from DCt of cancer tissues.
Fold change in the gene was calculated by the equation 2-DDCt
(Livak and Schmittgen, 2001; Pfaffl, 2001).
Statistical analysis
Mann–Whitney test was used to compare the difference in
plasma miRNA concentration and miRNA ratio between the
cancer group and the healthy group, and Wilcoxon test was used to
compare the paired plasma samples before and 1-month after
gastrectomy. P-value o0.05 was considered significant. Receiver-
operating characteristic (ROC) curves and the area under the
ROC curve (AUC) were used to assess the feasibility of using
plasma miRNA concentration as diagnostic tools for detecting
GC. We used the Youden index for identification of the optimal
cut-off point.
RESULTS
Evaluation of quantitative RT-PCR for measuring the
miRNAs in plasma sample
To evaluate the appropriateness of this plasma assay, we first
conducted amplification by real-time RT-PCR assay of a 10-fold
serial dilution of the mirVana miRNA Reference Panel. The
linearity of the quantitative RT-PCR was confirmed from the
concentrations of 1 to 0.0001fmol of each synthetic miRNAs,
such as miR-21, miR-106b and let-7a (R
2¼0.999, 0.998 and
0.999 respectively) between the logarithm of the amount of input
miRNAs and the Ct values (Figure 1). Using this assay, we found
circulating miRNAs (miR-21, miR-106b, and let-7a) detectable
and amplified in all samples from 34 GC patients and 15 healthy
volunteers. The concentrations of miR-106b were significantly
higher, whereas those of let-7a were significantly lower in plasma
from GC patients than in that from healthy controls (P¼0.002 and
o0.001 respectively; Figure 2B and C). However, there was no
significant difference in the concentration of miR-21 between GC
patients and controls, although it tended to be higher in GC
patients (P¼0.088; Figure 2A).
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Figure 1 Standard curve of miR-21, miR-106b, let-7a using synthetic
miRNAs. Ten-fold serial dilution of synthetic miRNA was used to generate
the standard curves. Linearity was confirmed within these concentrations,
ranging from 1 to 0.0001fmol. (miR-21: y¼ 3.7544xþ14.318
(R
2¼0.999); miR-106b: y¼ 3.9849xþ15.645 (R
2¼0.998); let-7a:
y¼ 3.4988xþ14.875 (R
2¼0.999))
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sRelationship between the miRNAs in plasma and primary
gastric cancer tissues
There were eight patients whose miR-106b concentrations
exceeded the highest level of healthy volunteers, and let-7a concen-
trations were below the lowest value of healthy volunteers. Then we
examined expressions of these miRNAs in cancer tissues compared
with those in adjacent normal tissues from these eight patients.
All the miRNAs obtained from formalin-fixed paraffin-embedded
tissues were amplified, and found to be of good quality for
amplification (data not shown). MiR-106b showed higher expres-
sion in primary GC tissues than normal mucosa in seven of the
eight patients analysed (87.5%), whereas let-7a showed lower
expression in seven patients (87.5%) (Table 1).
Then, the concentrations of miR-21 and miR-106b were analysed
in paired pre- and post-operative plasma samples from 10 GC
patients who underwent gastrectomy. Both miRNAs were signi-
ficantly reduced in post-operative samples compared with the
levels in pre-operative samples (P¼0.013 and 0.022 respectively;
Figure 3). These findings showed that primary cancer tissues and
plasma samples from most patients showed similar tendencies
concerning the miRNA levels, and indicated that the level of
plasma miRNAs might reflect the expression level of tumour
miRNAs.
Large-scale validation on plasma samples
In total, 69 GC patients were included in this study; 38 patients
with TNM stage I, 13 with stage II, 14 with stage III and 4 with
stage IV. We analysed another two miRNAs, miR-17-5p and miR-
106a, for large-scale validation. The plasma concentrations of
miRNAs, miR-17-5p, miR-21, miR-106a and miR-106b, were signi-
ficantly higher in GC patients than in controls (P¼0.006, 0.05,
0.008 and o0.001 respectively), whereas the concentration of
let-7a was significantly lower in GC patients than in controls
(P¼0.002; Figure 4). Analyses of the ROC curves for plasma
miRNAs showed that the AUC was greatest for miR-106b
(AUC¼0.721; Figure 5). To investigate more sensitive plasma
diagnostic biomarkers, we analysed the ratio of circulating miRNA
levels, dividing the plasma concentrations of miR-17-5p, miR-21,
miR-106a and miR-106b by that of let-7a, and then, the ratio of
miR-21 miR-106b
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Figure 2 Plasma miRNAs concentration in the initial analysis. Real-time RT-PCR assay, circulating plasma miRNAs (A: miR-21, B: miR-106b and C: let-7a)
were detectable and amplified in all samples from 34 gastric cancer patients and 15 healthy volunteers. The concentrations of miR-106b and let-7a were
significantly higher and lower in plasma from gastric cancer patients than in that from healthy controls (P¼0.002 and o0.001 respectively). However,
there was no significant difference in the concentration of miR-21 between gastric cancers patients and controls although it tended to be higher in gastric
cancer patients (P¼0.088). The upper and lower limits of the boxes and the lines inside the boxes indicate the 75th and 25th percentiles and the median
respectively. The upper and lower horizontal bars denote the 90th and 10th percentiles respectively.
Table 1 Expression of mature miRNAs in gastric cancer tissue vs those
in normal tissue
miR-106b let-7a
Case 1 1.344 0.722
Case 2 1.357 0.681
Case 3 1.241 0.880
Case 4 0.346 0.515
Case 5 3.812 3.659
Case 6 9.966 0.129
Case 7 1.608 0.139
Case 8 2.897 0.260
Rate of higher expression level in gastric cancer tissue 87.5% 12.5%
Rate of lower expression level in gastric cancer tissue 12.5% 87.5%
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smiR-106a/let-7a showed the highest AUC of 0.879 (Figure 6). In
this model, an optimal cut-off point was indicated at 0.536 with a
sensitivity of 85.5% and a specificity of 80.0%. Other analyses of
the ROC curves are shown in supplementary date (Supplementary
Figures 1 and 2).
DISCUSSION
Numerous genetic and epigenetic alterations are known to be
involved in tumourigenesis and tumour progression of various
cancers. Several studies have identified tumour-specific alterations
P=0.013 P=0.022
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Figure 3 Comparison of plasma miR-21 and miR-106b concentrations between pre- and post-operative samples from gastric cancer patients. Expressions
of both miRNAs were significantly reduced in plasma samples obtained 1 month after surgical removal of the tumour.
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Figure 4 Box plots of the plasma miRNA concentrations in gastric cancer patients and controls. Plasma miRNA concentrations were significantly
higher for miR-17-5p (P¼0.05), miR-21 (P¼0.006), miR-106a (P¼0.008) and miR-106b (Po0.001) in the gastric cancer patients compared to those
in controls, whereas let-7a was significantly lower in gastric cancer patients (P¼0.002) . The upper and lower limits of the boxes and the lines inside
the boxes indicate the 75th and 25th percentiles and the median respectively. The upper and lower horizontal bars denote the 90th and 10th percentiles
respectively.
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the potential of plasma circulating nucleic acids to be new non-
invasive biomarkers in patients with various cancers (Sidransky,
1997; Anker et al, 2001; Taback and Hoon, 2004; Chan and Lo,
2007).
However, during the past decade, non-coding RNAs, so-called
microRNAs (miRNAs), have also been shown to regulate gene expres-
sion by targeting mRNAs for translational repression or cleavage.
Consequently, these miRNAs have recently been identified as new
factors related to oncogenesis and tumour progression in various
cancers (He et al, 2005, 2008; Lu et al, 2005; Calin and Croce, 2006).
Mitchell et al (2008) recently reported that miRNAs are detect-
able in plasma and that circulating miRNAs have the potential
to be new biomarkers in patients with prostate cancers. They
also showed the high stability of plasma miRNAs after prolonged
incubation at room temperature and/or multiple freezing–thawing
processes. In addition to this high stability, the characteristics
of miRNAs such as tissue-specific miRNA signatures and the avail-
ability of many copies per cell would indicate potential advantages
as biomarkers compared with those of other nucleic acids, such as
circulating DNA and mRNA. In fact, accumulating reports also
suggest the potential of miRNAs in the early detection of patients
with several malignancies, such as lymphoma, colorectal cancer,
tongue cancer and ovarian cancer (Lawrie et al, 2008; Wong et al,
2008; Ng et al, 2009; Resnick et al, 2009).
These findings prompted us to investigate the usefulness
of miRNAs in patients with GCs. In this report, we selected four
miRNAs (miR-17-5p, miR-21, miR-106a and miR-106b) that have
been reported to be upregulated in GC, and also selected let-7a,
which has been reported to be downregulated in GC (Zhang et al,
2007, 2008; Chan et al, 2008; Motoyama et al, 2008; Guo et al, 2009;
Kim et al, 2009). First, we confirmed a linear correlation between
the logarithm of the amount of input synthetic miRNA and the
cycle threshold value on real-time PCR as well as the feasibility
of extracting total RNA and amplifying specific miRNA in plasma
samples. On the basis of these results, we used the absolute
concentration method for measuring plasma miRNAs in this
study. Some investigators have determined quantities of plasma
miRNAs by comparing internal control miRNAs (Ng et al, 2009;
Resnick et al, 2009). However, which miRNA is suitable as an
internal control for plasma assay remains controversial.
Next, we investigated whether plasma miRNAs could be released
from the primary gastric tumours. The comparison between
expressions of miRNA in plasma and primary tumour tissues
demonstrated that plasma and primary GC tissue samples showed
similar tendencies concerning the expression of miRNAs in almost
all cases. Each patient, however, showed a different pattern of
miRNA levels, high plasma miR-106b with a low expression in GC
tissue and low plasma let-7a with a high expression in cancer
tissue. Although the reason for these discrepancies remains to
be identified, one possible explanation for this finding is the
heterogeneity of the primary tumours. We also measured
circulating miRNAs in paired plasma before and 1 month after
surgical removal of the tumours, to confirm tumour release of the
circulating miRNAs. As a result, the concentrations of miR-21 and
miR-106b were significantly reduced postoperatively in patients
with high pre-operative plasma miR-21 and miR-106b. The kinetics
and metabolism of the plasma miRNAs have not yet been clearly
elucidated, however 1 month seems to be sufficient time for
clearance of the circulating miRNAs.
Finally, we performed a large-scale study by increasing the
number of plasma samples from GC patients and healthy
volunteers to validate the diagnostic potential of plasma miRNAs.
We found that the plasma concentrations of miRNAs, miR-17-5p,
miR-21, miR-106a and miR-106b were significantly higher in GC
patients than in controls, and the ROC analysis showed the greatest
AUC value for miR-106b. Although, the concentration of let-7a was
significantly lower in GC patients than in controls, contrary to our
expectation, we have also found that a certain miRNA that was
reported to be downregulated in primary cancer tissues showed a
lower plasma expression level in oesophageal cancer patients (data
not shown). Because circulating miRNAs are considered to have
been released from cancer tissues as well as from normal tissues,
the majority are expected to have originated from normal tissues.
Several recent reports suggested that plasma miRNAs might be
protected in a complex with other molecules, such as exosomes,
proteins and lipids (Valadi et al, 2007; Mitchell et al, 2008). The
protection of miRNAs might be greater in GC patients than
controls. An alternative hypothesis is that a lower plasma expres-
sion of certain miRNAs might be due to alterations in miRNA
expressions in normal tissues of cancer patients by unknown
mechanisms.
Determining the expression ratios of genes or miRNAs has been
reported to be a useful technique to improve diagnostic potential
(Gordon et al, 2002; Avissar et al,2 0 0 9 ) .T h e r e f o r e ,w ea l s o
investigated the miRNA expression ratios by dividing the plasma
concentration of upregulated miRNA (miR-17-5p, miR-21, miR-106a
and miR-106b) by that of downregulated miRNA (let-7a)t oi m p r o v e
the sensitivity and specificity of plasma miRNA assay for use as
diagnostic biomarkers. Then, the ratio of miR-106a/let-7a showed
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Figure 5 Receiver-operating characteristic (ROC) curve analysis in the
concentration of miR-106b assay for detecting gastric cancer patients.
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Figure 6 Receiver-operating characteristic (ROC) curve analysis of the
ratio of miR-106a/let-7a assay for detecting gastric cancer patients.
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satisfactory for clinical application.
Plasma miRNA assays have several potential clinical uses: screening
patients at high risk for GC and monitoring disease recurrence during
the follow-up period after gastrectomy. These miRNA biomarkers
might also be powerful and useful for confirming the completeness
of tumour resection and evaluating the efficacy of adjuvant therapies
if the elimination clearance of plasma miRNAs can be elucidated.
In conclusion, plasma miRNAs may be available as a new
marker for GC. Further prospective clinical trials using a variety of
plasma miRNAs should be carried out to define the usefulness
of the assay for each potential application.
Supplementary Information accompanies the paper on British
Journal of Cancer website (http://www.nature.com/bjc)
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